**ORIGINAL ARTICLE – CANCER RESEARCH**



# **N6 ‑methyladenosine (m6 A) reader IGF2BP2 stabilizes HK2 stability to accelerate the Warburg efect of oral squamous cell carcinoma progression**

**Ke Xu1 · Xiaojuan Dai1 · Jiankun Wu1 · Kai Wen2**

Received: 22 February 2022 / Accepted: 25 May 2022 / Published online: 28 June 2022 © The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature 2022

## **Abstract**

**Purpose** The N<sup>6</sup>-methyladenosine (m<sup>6</sup>A) has been involved in the regulation of cell proliferation and metastasis in multiple cancers. However, the biological significance of m<sup>6</sup>A reader IGF2BP2 in oral squamous cell carcinoma (OSCC) and the mechanism of IGF2BP2 itself have not been fully investigated.

**Methods** The cellular phenotypes of OSCC cells were determined by CCK-8 and transwell migration assays. The energy metabolism was detected using glucose uptake/lactate production assay and extracellular acidifcation rate analysis. The molecular interaction was tested by RNA immunoprecipitation assay.

**Results** Here, results indicated that IGF2BP2 was up-regulated in OSCC and that it acted as a predictor of poor prognosis. IGF2BP2 promoted the proliferation, migration and Warburg efect of OSCC cells in vitro. Mechanistical assays illustrated that IGF2BP2 directly interacted with HK2 mRNA by binding the 3'-UTR m<sup>6</sup>A site. Moreover, IGF2BP2 positively promoted the stability of HK2 mRNA and thus the protein level of HK2 increased upon IGF2BP2 overexpression.

**Conclusions** In conclusion, the IGF2BP2/m<sup>6</sup>A/HK2 axis accelerated the abnormal energy metabolism of OSCC. Taken together, these fndings revealed a novel mechanism by which IGF2BP2 functions in OSCC progression, which may provide new therapy options for OSCC patients.

**Keywords** Oral squamous cell carcinoma · N<sup>6</sup>-methyladenosine · IGF2BP2 · HK2 · Warburg effect

# **Introduction**

Oral squamous cell carcinoma (OSCC) acts as the most common malignant head and neck tumors, accounting for 80–90% of head and neck malignancy (Metsäniitty et al. [2021](#page-9-0); van der Kamp et al. [2022\)](#page-9-1). To make matters worse, the incidence rate and mortality have continued to rise in recent years (Bienkowska et al. [2021](#page-9-2)). Despite the marked improvement made by recent advances, including radiotherapy and chemotherapy, the mortality of OSCC is still high, especially the very low 5-year survival rate (Shahoumi [2021](#page-9-3); Haldar and Singh [2022\)](#page-9-4). High metastasis or insensitivity to

 $\boxtimes$  Ke Xu xuke9061@vip.sina.com chemotherapy is still one of the critical factors for the poor prognosis of OSCC. Nevertheless, whether and how OSCC could be efectively treated is largely unclear.

 $N^6$ -methyladenosine (m<sup>6</sup>A), one of the most abundant chemical modifcations of mRNAs in eukaryotes, has been reported to play a signifcant role in many human tumors (Chen et al. [2022](#page-9-5); Huang et al. [2021\)](#page-9-6). The methyltransferase, also known as "writers", activates the  $m<sup>6</sup>A$  activity by installing m<sup>6</sup>A in nitrogen atoms (Relier et al. [2022\)](#page-9-7). The demethylase, also known as "erasers", wipes off the  $m<sup>6</sup>A$ from the methylated RNA (Mu et al. [2022\)](#page-9-8). Moreover, the recognition protein, also known as "readers", recognizes the m<sup>6</sup>A-modified RNAs to stabilize or degrade them (Li et al. [2021a](#page-9-9); Tong et al. [2021](#page-9-10)). numerous papers have reported the functions of  $m<sup>6</sup>A$  methyltransferase in OSCC,. For instance, methyltransferase METTL3 is consistently up-regulated in OSCC samples and the high expression is associated with OSCC poor prognosis. Moreover, METTL3 mediates the m<sup>6</sup>A modification of BMI1 mRNA in its 3'-UTR to promote BMI1 translation under the cooperation with IGF2BP1

<sup>1</sup> Department of Stomatology Clinic, Cangzhou Central Hospital, Cangzhou 061000, Hebei, China

<sup>2</sup> Department of Maxillofacial Surgery, Cangzhou Central Hospital, Cangzhou 061000, Hebei, China

(Liu et al. [2020](#page-9-11)). Moreover, demethylase also regulates the tumorigenesis of FTO. For example, the fat mass and obesity-associated protein (FTO) is signifcantly up-regulated in areca nut-chewing OSCC tissue samples. The depletion of FTO attenuates the arecoline-induced chemoresistance and oncogenicity through negatively regulating transcription factor forkhead box protein A2 (Li et al. [2021b\)](#page-9-12).

Regarding  $m<sup>6</sup>A$  reader, the functions and potential mechanism are still unclear. Insulin-like growth factor 2 mRNAbinding protein 2 (IGF2BP2) is a critical  $m<sup>6</sup>A$  reader responsible for recognizing the  $m<sup>6</sup>A$  modification site. Here, we performed functional assays to investigate the function and mechanism of IGF2BP2 in OSCC. In the present research, we found that IGF2BP2 was up-regulated in the OSCC tissue and cells. IGF2BP2 combined with the  $m<sup>6</sup>A$  modification site at 3'-UTR of HK2 mRNA.

# **Materials and methods**

## **Clinical samples**

The OSCC tissue of patients who underwent surgery were gathered. None of the OSCC patients received radiotherapy or chemotherapy before surgery. After resection, tissue specimens were immediately stored in liquid nitrogen and subsequently stored at − 80 °C. Diagnosis was pathologically confrmed by two independent pathologists.

## **Cell culture**

OSCC cells (SCC-9, CAL-27) and normal oral epithelium keratinocytes (HOK) were obtained from the Cell Bank of the Chinese Academy of Sciences (Shanghai, China) and cultured in DMEM with 10% fetal bovine serum (FBS) and streptomycin and penicillin (1%, GE Healthcare, Chicago, IL, USA).

## **Cell transfection**

To up-regulate or silence the expression of IGF2BP2, full length and shRNA sequence against IGF2BP2, as well as empty vectors, were ligated into pIRES2-EGFP vector or pGPU6/GFP/Neo vector, respectively (GenePharma). Cells were plated in a 24-well culture dish at 70–80% confuence, and transfection was performed using Lipofectamine LTX Reagent (Life Technologies, Carlsbad, CA, USA) according to the manufacturer's protocol. The transfection efficiency was identifed using qRT-PCR.

#### **Western blotting**

For the OSCC cells, total proteins were extracted and subjected to 10% SDS-PAGE for separation and then transferred to PVDF membranes. Primary antibodies (anti-IGF2BP2, 1:1000, Abcam, ab128175) were used for incubation on nonfat milk-blocked PVDF membranes at 4 °C overnight. After incubation, the PVDF membranes were rinsed with Tris-buffered saline containing Tween 20 and further incubated with secondary antibody for 1 h at room temperature. Lastly, a chemiluminescence detection kit was used to detect the signals from diferent proteins. The relative integrated density values were analyzed using ImageJ software.

#### **Real‑time quantitative PCR (RT‑qPCR)**

Firstly, the total RNA was extracted from OSCC cells using TRI Reagent and the extracted RNA was quantifed. Then, the cDNA was reversely transcribed using PrimeScript RT reagent kit (Takara, Dalian, China). Subsequently, the relative expressions of IGF2BP2 and HK2mRNA were examined using SYBR green dye (Toyobo, Osaka, Japan) by a PCR reaction system, including a cDNA template  $(3 \mu L)$ , SYBR green dye (10  $\mu$ L), ddH2O (6.5  $\mu$ L) and paired primers (0.5  $\mu$ L, final concentration: 0.3  $\mu$ M). The quantitative gene expression of each group was detected  $(2^{-\Delta\Delta CT})$ . The premiers are listed in Table S1.

#### **CCK‑8 assay**

A cell proliferation assay was carried out by CCK-8 (Dojindo Laboratories) according to the protocol of the manufacturer. Approximately. 2000 per/well OSCC cells were seeded in six-well plates. After culturing for 48 h, the cells were added with 10 mL CCK-8 solutions. After that, the OD value was measured using Thermomax microplate reader (bio-tekEL) at 450 nm wavelengths.

#### **Transwell migration assay**

Transwell migration assay was performed using Transwell inserts (8  $\mu$ m pore size; Costar). About  $2 \times 10^4$  OSCC cells in serum‐free medium were seeded into the upper chamber uncoated with Matrigel (BD Biosciences, San Jose, CA). In the lower chamber, completed DMEM medium was flled. After 24 h of culturing, the cells through the upper chamber were removed and then fxed with 4% paraformaldehyde and stained with 0.1% crystal violet. The migrated cell numbers were counted under a light microscope.

#### **Glucose uptake and lactate production assay**

After transfection, OSCC cells were cultured and then replaced by high-glucose culture medium. After 24 h, the supernatants of OSCC culture medium were collected separately. The glucose uptake was detected using a glucose assay kit (BioVision, Milpitas, California, USA). The lactate production was detected using a lactate assay kit (BioVision) according to the manufacturer's instructions.

## **Measurement of extracellular acidifcation rate (ECAR)**

The extracellular acidifcation rate (ECAR) was estimated as previously described using Seahorse XF Glycolysis Stress Test Kit according to the manufacturer's instructions (Chen et al. [2018\)](#page-9-13). In brief, the OSCC cells  $(1 \times 10^4 \text{ cells/well})$ were seeded into Seahorse XF 96-cell culture microplates for adhere culture overnight. Then, cells were washed with DMEM medium supplemented with l-glutamine (2 mM,  $pH = 7.4$ ) and incubated at 37 °C for 1 h in CO<sup>2</sup>-free incubator. The glycolysis rate and glycolytic capacity were detected using Seahorse XF 96 Extracellular Flux Analyzer (Agilent Technologies, Santa Clara, CA, USA).

#### **Half‑life measurement**

To analyze the stability of HK2 mRNA, half-life assay was performed with the treatment of transcriptional inhibitor actinomycin D (Act D). OSCC cells were treated with actinomycin D (2 mg/mL, Sigma-Aldrich, Louis, MO, USA) to halt the transcription and then harvested at 0, 3 and 6 h after the treatment. The cellular RNAs were isolated and analyzed using qRT-PCR. Beta-actin acted as an internal reference.

#### **RNA immunoprecipitation (RIP) assay**

RIP assays were performed using EZ-Magna RIP Kit (Millipore) according to the manufacturer's protocol. SCC-9 and CAL-27 cells were lysed in complete RIP lysis bufer (Magna RIP Kit, Millipore, MA, USA) at 4 °C via disruptive sonication. Protein A/G agarose beads were conjugated with specifc antibodies (anti-IGF2BP2, 11601-1-AP, Proteintech, China) or control IgG and then incubated with cell extract for 2 h at 4 °C. HK2 mRNA was analyzed through quantitative reverse-transcription polymerase chain reaction (qRT-PCR).

#### **Xenograft mouse model**

Male BALB/c nude mice (5–6 weeks of age) were provided by Type Culture Collection of the Chinese Academy of Medical Sciences (Beijing, China) and acclimatized for a

week prior to this assay. Nude mice were subcutaneously injected with  $5 \times 10^6$  CAL27 cells. Every 5 days, the tumor weight and length week were monitored with a caliper for the tumor volume following the formula  $(0.52 \times a \times b^2, a$  for the long and *b* for the short diameter, respectively). After 30 days, mice were killed and tumors were dissected out for weight. The assay was approved by the Ethics Committee of Cangzhou Central Hospital.

#### **Statistical analysis**

Data are expressed as means $\pm$ SD (standard deviation). Comparison was performed using variance analysis. Least signifcant diference procedure analysis was performed when there were more than two groups.  $P$  value <0.05 was considered statistically signifcant.

## **Results**

# **IGF2BP2 was highly expressed in OSCC tumor tissue cohort and cells**

Given the critical roles of  $m<sup>6</sup>A$  methylation key enzymes in human cancer, we focused on the novel  $m<sup>6</sup>A$  reader IGF2BP2 in OSCC. Firstly, the large cohort data survey based on TCGA (<https://www.tcga.org/>) found that the expression of IGF2BP2 was signifcantly up-regulated in the HNSC cohort (Fig. [1A](#page-3-0)). Because OSCC was a subclass of HNSC, the data from the database indicated that IGF2BP2 was over-expressed in OSCC, which might act as an oncogene in OSCC. Moreover, the level of IGF2BP2 mRNA was found to be up-regulated in OSCC cells (SCC-9, CAL-27) (Fig. [1B](#page-3-0)). Moreover, the IGF2BP2 protein was detected using western blot analysis and it was found that the IGF2BP2 protein was up-regulated in OSCC cells (SCC-9, CAL-27) (Fig. [1C](#page-3-0)). With regard to the survival rate of OSCC with high/low IGF2BP2 expression, public database GEPIA ([http://gepia.cancer-pku.cn/index.html\)](http://gepia.cancer-pku.cn/index.html) (Fig. [1D](#page-3-0)) and Kaplan–Meier plotter ([http://kmplot.com/analysis/\)](http://kmplot.com/analysis/) (Fig. [1E](#page-3-0)) revealed that patients with high IGF2BP2 expression had close correlation with low survival rate. Overall, the above data indicated that IGF2BP2 was highly expressed in OSCC and might function as a risk factor for OSCC.

## **IGF2BP2 promoted the migration, proliferation and Warburg efect (aerobic glycolysis) of OSCC**

To investigate the function of IGF2BP2 in OSCC, IGF2BP2 overexpression or knockdown transfection was performed in the OSCC cells (SCC-9, CAL-27). The transfection efficiency was detected using RT-PCR and western blot (Fig. [2A](#page-6-0), B). Transwell migration assay indicated that



<span id="page-3-0"></span>**Fig. 1** IGF2BP2 was highly expressed in OSCC tumor tissue cohort and cells. **A** The large cohort data survey based on TCGA ([https://](https://www.tcga.org/) [www.tcga.org/\)](https://www.tcga.org/) revealed the up-regulated expression of IGF2BP2 in an HNSC cohort. **B** RT-PCR was performed to detect the expression of IGF2BP2 in OSCC cells (SCC-9, CAL-27). **C** Western blot analysis was performed to analyze the IGF2BP2 protein level in OSCC

cells (SCC-9, CAL-27). **D** Public database GEPIA ([http://gepia.can](http://gepia.cancer-pku.cn/index.html)[cer-pku.cn/index.html\)](http://gepia.cancer-pku.cn/index.html) revealed the survival rate of OSCC with high/ low IGF2BP2 expression. **E** Kaplan–Meier plotter ([http://kmplot.](http://kmplot.com/analysis/) [com/analysis/\)](http://kmplot.com/analysis/) showed the survival rates of OSCC patients with high/ low IGF2BP2 expression. \**p*<0.05; \*\**p*<0.01

IGF2BP2 overexpression accelerated the migration of SCC-9 cells, and IGF2BP2 knockdown reduced the migration of CAL-27 cells (Fig. [2](#page-6-0)C). CCK-8 assays illustrated that IGF2BP2 overexpression promoted the proliferation of SCC-9 cells, and IGF2BP2 knockdown decreased the proliferation of CAL-27 cells (Fig. [2](#page-6-0)D). Glucose uptake analysis (Fig. [2](#page-6-0)E) and lactate production analysis (Fig. [2](#page-6-0)F) found that IGF2BP2 overexpression accelerated the glucose uptake and lactate production of SCC-9 cells, while IGF2BP2 knockdown reduced the glucose uptake and lactate production of CAL-27 cells. Extracellular acidifcation rate (ECAR) analysis displayed that IGF2BP2 overexpression accelerated the acidifcation rate of SCC-9 cells and IGF2BP2 knockdown weakened the acidifcation rate of CAL-27 cells (Fig. [2G](#page-6-0)). Overall, the above data indicated that IGF2BP2 promoted the migration, proliferation and aerobic glycolysis of OSCC.

# **IGF2BP2 targeted HK2 mRNA via the m6 A modifcation site**

To discover the potential targets for IGF2BP2, we detected the expression levels of aerobic glycolysis markers (GLUT1, HK2, LDHA). Results indicated that HK2 showed signifcant overexpression upon IGF2BP2 up-regulation (Fig. [3](#page-6-1)A), and decreased levels upon IGF2BP2 silencing (Fig. [3B](#page-6-1)). In public database, HK2 expression was positively correlated to IGF2BP2 expression (Fig. [3](#page-6-1)C). Using SRAMP online tools (<http://www.cuilab.cn/sramp>), we found that there were several potential  $m<sup>6</sup>A$  sites in the HK2 genomic sequences (Fig. [3D](#page-6-1)). Therefore, we noticed that IGF2BP2 targeted HK2 mRNA via the  $m<sup>6</sup>A$  modification site.

## **IGF2BP2 enhanced the stability of HK2 mRNA via an m6 A‑dependent manner**

We found that HK2 acted as a target of IGF2BP2, and IGF2BP2 might target HK2 via m<sup>6</sup>A modification. Subsequently, the IGF2BP2 motif was identifed ([https://rna.](https://rna.sysu.edu.cn/rmbase/) [sysu.edu.cn/rmbase/\)](https://rna.sysu.edu.cn/rmbase/) (Fig.  $4A$ ). The potential m<sup>6</sup>A modifcation site on the HK2 genome was identifed (GGACU). RIP-qPCR assay revealed that, compared with the control IgG, IGF2BP2 antibody-precipitated complexes enriched the expression of HK2 mRNA in OSCC (Fig. [4B](#page-7-0)). RNA stability assay indicated that IGF2BP2 overexpression upregulated the enrichment of HK2 mRNA, while IGF2BP2 silencing decreased the HK2 mRNA enrichment (Fig. [4C](#page-7-0), D). Western blot analysis found that IGF2BP2 overexpression up-regulated the enrichment of HK2 protein, while IGF2BP2 silencing decreased the HK2 protein enrichment (Fig. [4](#page-7-0)E, F). Overall, these data suggested that IGF2BP2 enhanced the stability of HK2 mRNA via an  $m<sup>6</sup>A$ -dependent manner.

## **IGF2BP2/HK2 promoted the aerobic glycolysis of OSCC**

Given that HK2 acts as a pivotal element in aerobic glycolysis, we investigate the potential role of IGF2BP2/HK2 in OSCC aerobic glycolysis. Glucose uptake analysis (Fig. [5A](#page-8-0)) and lactate production analysis (Fig. [5B](#page-8-0)) found that HK2 overexpression promoted the glucose uptake and lactate production of OSCC cells (CAL-27 cells), then IGF2BP2 knockdown (sh-IGF2BP2-1#) reduced the glucose uptake and lactate production, respectively. Then, extracellular acidifcation rate (ECAR) analysis displayed that HK2 overexpression accelerated the acidifcation rate, while IGF2BP2 knockdown co-transfection weakened the acidifcation rate of CAL-27 cells (Fig. [5C](#page-8-0)). In vivo animal xenograft assay indicated that IGF2BP2 knockdown repressed the tumor growth (Fig. [5D](#page-8-0), E). Overall, these data suggested that IGF2BP2/HK2 promoted the aerobic glycolysis of OSCC.

## **Discussion**

Accumulating evidence has continued to implicate m6A in the pathological characteristics of a wide array of human tumors, including OSCC (Huang et al. [2020;](#page-9-14) Xu et al. [2021](#page-9-15)). Besides,  $m<sup>6</sup>A$  highlights its potential as a therapeutic target. However, the molecular mechanism by which  $m<sup>6</sup>A$  reader IGF2BP2 infuences OSCC remains largely unknown (Zhu et al.  $2021$ ; Ai et al.  $2021$ ). To explore the role of m<sup>6</sup>A regulatory reader enzymes IGF2BP2 in OSCC pathogenesis and uncover its regulatory mechanism, we performed a cluster of functional and mechanistic assays related to  $m<sup>6</sup>A$  (Fig. [6](#page-8-1)).

Increasing evidence suggests that various  $m<sup>6</sup>A$  key enzymes, such as IGF2BP1/2/3, METTL3 and ALKBH5, are implicated in a myriad of biological processes supporting cancer progression. For instance, METTL3 mediates the m<sup>6</sup>A modification of BMI1 mRNA in its 3'-UTR to promote BMI1 translation under the cooperation with IGF2BP1 (Liu et al. [2020\)](#page-9-11). Moreover, depletion of demethylase fat mass and obesity-associated protein (FTO) attenuates the arecoline-induced chemoresistance of OSCC through negatively regulating transcription factor FOXA2 (Li et al. [2021b](#page-9-12)). Methyltransferase-like 14 (METTL14) is up-regulated in OSCC and promotes proliferation, migration, and invasiveness of OSCC cells, which directly combines with eukaryotic translation initiation factor gamma 1 (eIF4G1) mRNA and decreases its mRNA stability (Wang et al. [2021\)](#page-9-18). Taken together, these data suggest that  $m<sup>6</sup>A$  is wildly involved in the tumorigenesis and progression of OSCC.

Given that OSCC is one of the most common malignancies worldwide and aerobic glycolysis acts as an essential factor in the tumorigenesis of OSCC, we designed and performed the current study to analyze the potential role of  $m<sup>6</sup>A$ 



on OSCC aerobic glycolysis. The present study analyzed the expression of IGF2BP2 in OSCC tissue samples and cells, indicating that IGF2BP2 level increased both in tissue

samples and cells and correlated with the poor prognosis. Moreover, bio-functional assays suggested that IGF2BP2 promoted the migration, proliferation, and aerobic glycolysis

<span id="page-6-0"></span>**Fig. 2** IGF2BP2 promoted the migration, proliferation and Warburg ◂ efect (aerobic glycolysis) of OSCC. **A** IGF2BP2 overexpression or **B** knockdown transfection was performed in the OSCC cells (SCC-9, CAL-27). The transfection efficiency was detected using RT-PCR and western blot, respectively. **C** Transwell migration assay indicated the migration of SCC-9 cells of IGF2BP2 overexpression and IGF2BP2 knockdown of CAL-27 cells. **D** CCK-8 assays illustrated the proliferation of SCC-9 cells of IGF2BP2 overexpression and IGF2BP2 knockdown of CAL-27 cells. **E** Glucose uptake analysis and **F** lactate production analysis revealed the glucose uptake and lactate production of SCC-9 cells of IGF2BP2 overexpression and IGF2BP2 knockdown of CAL-27 cells. **G** Extracellular acidification rate (ECAR) analysis displayed the acidifcation rate of SCC-9 cells and CAL-27 cells. \**p*<0.05; \*\**p*<0.01

of OSCC. These data illustrated that IGF2BP2 may act as an oncogene in the OSCC.

Although many risk factors have been reported to be involved in the tumorigenesis and progression of OSCC, the critical pathogenic factors for malignant tumor are closely correlated with abnormal energy metabolism. Aerobic glycolysis is an important energy-providing method for tumor physiological activities, such as diferentiation and

proliferation. Moreover, glycolysis provides abundant energy supply for OSCC and participates in malignancy progression. In the progression of aerobic glycolysis, key enzyme HK2 plays a critical role and numerous pathological processes are correlated with HK2.

Here, our research found that  $m<sup>6</sup>A$  reader IGF2BP2 directly combined with the  $m<sup>6</sup>A$  modification site on HK2 mRNA, thereby enhancing the RNA stability of HK2 mRNA. Then, the protein level of HK2 was also up-regulated upon IGF2BP2 overexpression and decreased upon IGF2BP2 silencing. In OSCC, HK2 has been identifed as an oncogene. For example, HK2 is highly expressed in OSCC patient-derived tissues and cells, and the depletion of HK2 repressed the OSCC cell growth in vivo and in vitro (Li et al. [2020\)](#page-9-19). Overall, our fnding demonstrated that HK2 may serve as a potential target of OSCC tumorigenesis.

In conclusion, elucidating the molecular mechanism related to aerobic glycolysis of OSCC cells is essential for the development of accurate diagnostic and individualized therapeutic strategies, which may signifcantly improve the prevention of OSCC.



<span id="page-6-1"></span>**Fig. 3** IGF2BP2 targeted HK2 mRNA via the  $m<sup>6</sup>A$  modification site. **A**, **B** RT-PCR analysis indicates the expression levels of aerobic glycolysis markers (GLUT1, HK2, LDHA) in SCC-9 cells with IGF2BP2 up-regulation, as well as in CAL-27 cells with n IGF2BP2 silencing. **C** The interaction within HK2 expression and IGF2BP2 expression

in an HNSC cohort in a public database [\(http://gepia.cancer-pku.cn/](http://gepia.cancer-pku.cn/index.html) [index.html\)](http://gepia.cancer-pku.cn/index.html). **D** SRAMP online tools [\(http://www.cuilab.cn/sramp](http://www.cuilab.cn/sramp)) revealed that there were several potential  $m<sup>6</sup>A$  sites in HK2 genomic sequences. \**p*<0.05; \*\**p*<0.01



<span id="page-7-0"></span>**Fig. 4** IGF2BP2 enhanced the stability of HK2 mRNA via an m6 A-dependent manner. **A** The IGF2BP2 motif was identifed ([https://rna.sysu.edu.cn/rmbase/\)](https://rna.sysu.edu.cn/rmbase/). GGACU w as the potential m<sup>6</sup>A modifcation site on the HK2 genome. **B** RIP-qPCR assay revealed the IGF2BP2 antibody-precipitated HK2 mRNA expression in OSCC

(SCC-9, CAL-27). **C**, **D** Shortened RNA lifetime of HK2 mRNA after IGF2BP2 overexpression (SCC-9) or knockdown (CAL-27). **E**, **F** Western blot analysis revealed the HK2 protein upon IGF2BP2 overexpression (SCC-9) or knockdown (CAL-27). \**p*<0.05; \*\**p*<0.01



<span id="page-8-0"></span>**Fig. 5** IGF2BP2/HK2 promoted the phenotype of OSCC. **A** Glucose uptake analysis and **B** lactate production analysis was detected in CAL27 cells transfected with HK2 overexpression plasmids or co-transfected with IGF2BP2 silencing (sh-IGF2BP2-1#). **C** Extra-



<span id="page-8-1"></span>**Fig. 6** IGF2BP2 promoted OSCC progression via an m<sup>6</sup>A-dependent manner

cellular acidifcation rate (ECAR) analysis displayed the acidifcation rate in CAL27 cells transfected with HK2 overexpression and/or IGF2BP2 knockdown (sh-IGF2BP2-1#). **D** In vivo tumor weight and **E** volume was calculated in mice

**Supplementary Information** The online version contains supplementary material available at <https://doi.org/10.1007/s00432-022-04093-z>.

**Author contributions** KX is responsible for assays and funding. XD, JW and KW acted as assistants.

**Funding** This study was supported by Cangzhou City Key Research and Development Project (Number: 204106118).

**Data availability** The analyzed data sets generated during the present study are available from the corresponding author on reasonable request.

#### **Declarations**

**Conflict of interest** The authors declare that they have no competing interests.

**Ethics approval** The present study was approved by the ethical review committee of the Cangzhou Central Hospital.

**Patient consent for publications** Not applicable.

#### **References**

- <span id="page-9-17"></span>Ai Y, Liu S, Luo H, Wu S, Wei H, Tang Z et al (2021) METTL3 intensifes the progress of oral squamous cell carcinoma via modulating the m6A amount of PRMT5 and PD-L1. J Immunol Res 2021:6149558. <https://doi.org/10.1155/2021/6149558>
- <span id="page-9-2"></span>Bienkowska KJ, Hanley CJ, Thomas GJ (2021) Cancer-associated fbroblasts in oral cancer: a current perspective on function and potential for therapeutic targeting. Front Oral Health 2:686337. <https://doi.org/10.3389/froh.2021.686337>
- <span id="page-9-13"></span>Chen Z, Zuo X, Zhang Y, Han G, Zhang L, Wu J, Wang X (2018) MiR-3662 suppresses hepatocellular carcinoma growth through inhibition of HIF-1α-mediated Warburg efect. Cell Death Dis 9:549. <https://doi.org/10.1038/s41419-018-0616-8>
- <span id="page-9-5"></span>Chen P, Hu J, Han X, Chen Y (2022) Advances in the functional roles of N<sup>6</sup>-methyladenosine modification in cancer progression: mechanisms and clinical implications. Mol Biol Rep. [https://doi.org/](https://doi.org/10.1007/s11033-022-07126-5) [10.1007/s11033-022-07126-5](https://doi.org/10.1007/s11033-022-07126-5)
- <span id="page-9-4"></span>Haldar A, Singh AK (2022) The association of long non-coding RNA in the prognosis of oral squamous cell carcinoma. Genes Genomics. <https://doi.org/10.1007/s13258-021-01194-w>
- <span id="page-9-14"></span>Huang GZ, Wu QQ, Zheng ZN, Shao TR, Chen YC, Zeng WS, Lv XZ (2020) M6A-related bioinformatics analysis reveals that HNRNPC facilitates progression of OSCC via EMT. Aging 12:11667–11684.<https://doi.org/10.18632/aging.103333>
- <span id="page-9-6"></span>Huang M, Xu S, Liu L, Zhang M, Guo J, Yuan Y et al (2021) m6A methylation regulates osteoblastic diferentiation and bone remodeling. Front Cell Dev Biol 9:783322. [https://doi.org/10.3389/fcell.](https://doi.org/10.3389/fcell.2021.783322) [2021.783322](https://doi.org/10.3389/fcell.2021.783322)
- <span id="page-9-19"></span>Li M, Gao F, Zhao Q, Zuo H, Liu W, Li W (2020) Tanshinone IIA inhibits oral squamous cell carcinoma via reducing Akt-c-Myc signaling-mediated aerobic glycolysis. Cell Death Dis 11:381. <https://doi.org/10.1038/s41419-020-2579-9>
- <span id="page-9-9"></span>Li H, Xiao W, He Y, Wen Z, Cheng S, Zhang Y, Li Y (2021a) Novel insights into the multifaceted functions of RNA n(6)-methyladenosine modifcation in degenerative musculoskeletal diseases. Front Cell Dev Biol 9:766020. [https://doi.org/10.3389/fcell.2021.](https://doi.org/10.3389/fcell.2021.766020) [766020](https://doi.org/10.3389/fcell.2021.766020)
- <span id="page-9-12"></span>Li X, Xie X, Gu Y, Zhang J, Song J, Cheng X, Gao Y, Ai Y (2021b) Fat mass and obesity-associated protein regulates tumorigenesis of arecoline-promoted human oral carcinoma. Cancer Med 10:6402– 6415.<https://doi.org/10.1002/cam4.4188>
- <span id="page-9-11"></span>Liu L, Wu Y, Li Q, Liang J, He Q, Zhao L et al (2020) METTL3 promotes tumorigenesis and metastasis through BMI1 m(6) A methylation in oral squamous cell carcinoma. Mol Therapy 28:2177–2190.<https://doi.org/10.1016/j.ymthe.2020.06.024>
- <span id="page-9-0"></span>Metsäniitty M, Hasnat S, Salo T, Salem A (2021) Oral microbiota—a new frontier in the pathogenesis and management of head and neck cancers. Cancers.<https://doi.org/10.3390/cancers14010046>
- <span id="page-9-8"></span>Mu H, Li H, Liu Y, Wang X, Mei Q, Xiang W (2022) N6-methyladenosine modifcations in the female reproductive system: roles in gonad development and diseases. Int J Biol Sci 18:771–782. <https://doi.org/10.7150/ijbs.66218>
- <span id="page-9-7"></span>Relier S, Rivals E, David A (2022) The multifaceted functions of the fat mass and obesity-associated protein (FTO) in normal and cancer cells. RNA Biol 19:132–142. [https://doi.org/10.1080/15476286.](https://doi.org/10.1080/15476286.2021.2016203) [2021.2016203](https://doi.org/10.1080/15476286.2021.2016203)
- <span id="page-9-3"></span>Shahoumi LA (2021) Oral cancer stem cells: therapeutic implications and challenges. Front Oral Health 2:685236. [https://doi.org/10.](https://doi.org/10.3389/froh.2021.685236) [3389/froh.2021.685236](https://doi.org/10.3389/froh.2021.685236)
- <span id="page-9-10"></span>Tong H, Wei H, Smith AO, Huang J (2021) The role of m6A epigenetic modifcation in the treatment of colorectal cancer immune checkpoint inhibitors. Front Immunol 12:802049. [https://doi.org/](https://doi.org/10.3389/fimmu.2021.802049) [10.3389/fmmu.2021.802049](https://doi.org/10.3389/fimmu.2021.802049)
- <span id="page-9-1"></span>van der Kamp MF, Halmos GB, Guryev V, Horvatovich PL, Schuuring E, van der Laan B et al (2022) Age-specifc oncogenic pathways in head and neck squamous cell carcinoma - are elderly a different subcategory? Cell Oncol (dordr). [https://doi.org/10.1007/](https://doi.org/10.1007/s13402-021-00655-4) [s13402-021-00655-4](https://doi.org/10.1007/s13402-021-00655-4)
- <span id="page-9-18"></span>Wang F, Zhu Y, Cai H, Liang J, Wang W, Liao Y et al (2021) N6-methyladenosine methyltransferase METTL14-mediated autophagy in malignant development of oral squamous cell carcinoma. Front Oncol 11:738406.<https://doi.org/10.3389/fonc.2021.738406>
- <span id="page-9-15"></span>Xu L, Li Q, Wang Y, Wang L, Guo Y, Yang R et al (2021) m(6)A methyltransferase METTL3 promotes oral squamous cell carcinoma progression through enhancement of IGF2BP2-mediated SLC7A11 mRNA stability. Am J Cancer Res 11:5282–5298
- <span id="page-9-16"></span>Zhu F, Yang T, Yao M, Shen T, Fang C (2021) HNRNPA2B1, as a m(6) A reader, promotes tumorigenesis and metastasis of oral squamous cell carcinoma. Front Oncol 11:716921. [https://doi.org/10.](https://doi.org/10.3389/fonc.2021.716921) [3389/fonc.2021.716921](https://doi.org/10.3389/fonc.2021.716921)

**Publisher's Note** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.